Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Paroxetine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 3/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | GRK2 | P25098 | 4/20 | 0.98 |
| ▸ | TP53 | P04637 | 2/20 | 0.98 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.98 |
| ▸ | LMNA | P02545 | 1/20 | 0.98 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.98 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.98 |
| ▸ | THPO | P40225 | 1/20 | 0.98 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.98 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.98 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.98 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.98 |
| ▸ | NPC1 | O15118 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Paroxetine SCHEMBL9398356 | 1.00 | CYP3A4 (1.00) | CYP3A4MEN1KMT2AUSP2GRK2 | |
| Paroxetine SCHEMBL9398351 | 1.00 | CYP3A4 (1.00) | CYP3A4MEN1KMT2AUSP2GRK2 | |
| Paroxetine SCHEMBL2847926 | 1.00 | CYP3A4 (1.00) | CYP3A4MEN1KMT2AUSP2GRK2 | |
| Paroxetine SCHEMBL6100418 | 1.00 | CYP3A4 (1.00) | CYP3A4MEN1KMT2AUSP2GRK2 | |
| Paroxetine SCHEMBL29437926 | 1.00 | CYP3A4 (1.00) | CYP3A4MEN1KMT2AUSP2GRK2 | |
| Paroxetine SCHEMBL5312626 | 1.00 | CYP3A4 (1.00) | CYP3A4MEN1KMT2AUSP2GRK2 | |
| Paroxetine SCHEMBL33348 | 1.00 | CYP3A4 (1.00) | CYP3A4MEN1KMT2AUSP2GRK2 | |
| Paroxetine SCHEMBL145268 | 0.99 | CYP3A4 (1.00) | CYP3A4MEN1KMT2AUSP2GRK2 | |
| Paroxetine SCHEMBL8184989 | 0.99 | CYP3A4 (0.98) | CYP3A4MEN1KMT2AUSP2GRK2 | |
| Paroxetine SCHEMBL145267 | 0.99 | CYP3A4 (1.00) | CYP3A4MEN1KMT2AUSP2GRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1670427-A4 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX INC (US) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007041584-A2 | IMPLANTABLE SENSORS, IMPLANTABLE PUMPS, AND ANTI-SCARRING DRUG COMBINATIONS | COMBINATORX, INCORPORATED (US) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007041593-A2 | ANTI-SCARRING DRUG COMBINATIONS AND USE THEREOF | COMBINATORX, INCORPORATED (US) | 2007-04-12 | — | — | WO | disclosed |
| EP-1670427-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | CombinatoRx, Incorporated (US) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005027839-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2005-03-31 | — | — | WO | disclosed |
| US-20040167227-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION | 2004-08-26 | — | — | US | disclosed |
| US-20030004188-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION | 2003-01-02 | — | — | US | disclosed |
| US-6133289-A | USING THE ANHYDRATE FORM AND A SOLVATE-FREE FORM TO TREAT OR PREVENT ALCOHOLISM, ANXIOLYITIC AGENTS, ANTIDEPRESSANTS, OBSESSIVE COMPULSIVE AND PANIC DISORDERS, CHRONIC PAIN, SENILE DEMENTIA, MIGRAINE, EATING DISORDERS, SOCIAL PHOBIA, | SMITHKLINE BEECHAM CORPORATION (US) | 2000-10-17 | — | — | US | disclosed |
| US-6080759-A | PAROXETINE HYDROCHLORIDE ANHYDRATE SUBSTANTIALLY FREE OF BOUND ORGANIC SOLVENT PREPARED BY DISPLACING THE SOLVENT WITH A DISPLACING AGENT; SUBSTANTIALLY FREE OF PROPAN-2-OL SUCH THAT IT IS OTHER THAN FORM Z; ANTIDEPRESSANTS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-06-27 | — | — | US | disclosed |
| US-5900423-A | SEROTONIN INHIBITOR | SMITHKLINE BEECHAM CORPORATION (US) | 1999-05-04 | — | — | US | disclosed |
| US-5872132-A | Form of paroxetine hydrochloride anhydrate | SMITHKLINE BEECHAM CORPORATION (US) | 1999-02-16 | — | — | US | disclosed |
| US-5856493-A | Process for making novel form of paroxeting hydrochloride anhydrate | SMITHKLINE BEECHAM CORPORATION (US) | 1999-01-05 | — | — | US | disclosed |